U-PGx Personalised Medicine Symposium

Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in pharmacogenomics and several commercially available pharmacogenomics tests, its application in routine patient care remains very limited. The U-PGx consortium will address major challenges and obstacles for implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important pharmacogenomics markers is cost-effective and results in a better outcome for patients. With the pre-emptive pharmacogenomics testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive pharmacogenomics testing will be conducted at a large scale in seven existing European health care environments in the Netherlands, Spain, UK, Italy, Austria, Greece, and Slovenia.

Organizing Committee

Henk-Jan Guchelaar (Leiden, NL)

Christina Mitropoulou (London, UK)

Jesse Swen (Leiden, NL)

 

Invited Speakers

Kelly Caudle

Sir Mark Caulfield

Arie Dijkstra

Marie Christine Etienne-Grimaldi

Dame Sue Hill

Marie-Anne Loriot

Andrew Monte

Jan Berkelmans 

Mike Pacanowski

George P. Patrinos

Sir Munir Pirmohamed

Matthias Samwald

Matthias Schwab 

Todd Skaar 

Christopher Stevens aka Lord Elpus

Jesse Swen

Scientific Program 

Day 1 – 30 March 2022

08.45 – 09.15: Welcome / coffee

09.15 – 09.30: Opening address by Prof Henk-Jan Guchelaar

09.30 – 11.00: Session UK Pharmacogenetics and Stratified Medicine Network

(Chair: Prof. Sir Munir Pirmohamed) 

09.30 – 10.00: Prof Sir Mark Caulfield

Pharmacogenomics and the 100,000 genomes project

10.00 – 10.30: Prof Dame Sue Hill

Implementing pharmacogenomics into the NHS

10.30 – 11.00: Prof Sir Munir Pirmohamed

Deep phenotype vs large datasets: moving pharmacogenomics forward

11.00 – 11.30: Coffee break

11.30 – 13.00: Session Spanish Infrastructure of Precision Medicine associated with Science and Technology (IMPaCT)

(Chair: Prof. Adrian Llerena) 

11.30 – 12.00: Prof. Angel Carracedo

IMPaCT: The national strategy of Personalised Medicine Genomic phrame

12.00 – 12.30: Prof. Adrian Llerena

Case example implementation: MedeA

12.30 – 13.00: Prof. Fernando Martin-Sanchez

The role of Digital Health in Personalised Medicine 

13.00 – 14.00:    Lunch break

14.00 – 16.00: Session Regulation & Society

(Chair: Prof. Magnus Ingelman-Sundberg-Sundberg)

14.00 – 14.30: Christopher Stevens aka Lord Elpus

DPD, A Testing Time

14.30 – 15.00: Jan Berkelmans 

The value of Personalized Medicine and Pharmacogenetics testing

15.00 – 15.30: George P. Patrinos

Harmonization of pharmacogenomics guidance: The European Medicines Agency and other international approaches

15.30 – 16.00: Michael Pacanowski

Regulatory considerations for genotype-guided therapy in the U.S.

16.00 – 16.30: Coffee break

16.30 – 18.00:   Session U-PGx consortium 

(Chair: Prof. Henk-Jan Guchelaar)

16.30 – 17.00: Matthias Samwald

Overcoming borders and barriers: Enabling PGx across Europe in the U-PGx project

17.00 – 17.30: Jesse Swen

Results of the PREPARE trial

17.30 – 18.00:Matthias Schwab

Future direction of systems pharmacology and personalized medicine

18.00 – 19.30: Dinner buffet

19.30 – 21.00: Session PGRN

(Chair: Dr. Andrew Monte)

19.30 – 20.00: Kelly Caudle

Resources for implementing pharmacogenetics into routine clinical practice

20.00 – 20.30: Todd Skaar 

Lessons learned from the pragmatic Pharmacogenetics-guided INGENIOUS trial

20.30 – 21.00: Andrew Monte

The PGRN: Globalizing PGx Research Collaboration

Day 2 – 31 March, 2022

08.45 – 09.00: Welcome / coffee 

09.00 – 10.30: Session FUSAFE network 

(Chair Marie Christine Etienne-Grimaldi)

09.00 – 09.30: Marie Christine Etienne-Grimaldi

Dihydropyrimidine deshydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: Results of FUSAFE individual patient data meta-analysis

09.30 – 10.00: Marie-Anne Loriot

French experience of nationwide implementation of uracilemia testing, and its impact on fluoropyrimidine-related toxicities based on pharmacovigilance data collection

10.00 – 10.30: Marie Christine Etienne-Grimaldi

Current perspectives of FUSAFE and other fluoropyrimidine pharmacogenetic projects

10.30 – 11.00:    Coffee break

11:00 – 12:30   Session European Society of Pharmacogenomics and Personalised Therapy 

(Chairs: Prof. Vangelis Manolopoulos and Prof. Adrian Llerena)

11.00 – 11.30 Vangelis Manolopoulos 

European Society of Pharmacogenomics and Personalised Therapy: The first 10 years

Direct oral anticoagulants: OMICS approaches for biomarker generation and personalised clinical implementation 

11.30 – 12.00 Ann Daly

Hepatic adverse drug reactions to antimicrobials: Predictable?

12.00 – 12.30 Ron H. van Schaik

Pharmacogenomics in clinical care: Harmonization of CYP2D6 testing and status of CYP3A4 genotyping

12.30 – 13.30:    Lunch break

13.30 – 15.00:    Session Socioeconomic aspects

(Chair: Prof. Henk-Jan Guchelaar)

13.30 – 14.00 Μatthijs Versteegh

The net and societal benefit of personalised medicine: Review and case study

14.00 – 14.30 David Haerry

Personalized medicine, an opportunity to redefine value in healthcare by incorporating patient preference and socio-economic aspects

14.30 – 15.00 Arie Dijkstra

Social psychology: What is the impact of the CoViD-19 pandemic on pre-emptive oharmacogenetic testing? 

15.00: Closing remarks – Prof. Henk-Jan Guchelaar